{"id":114,"date":"2010-04-26T16:27:38","date_gmt":"2010-04-26T14:27:38","guid":{"rendered":"http:\/\/www.pjh.fr\/wordpress\/?page_id=114"},"modified":"2010-04-26T16:27:38","modified_gmt":"2010-04-26T14:27:38","slug":"ipsswm-2009","status":"publish","type":"page","link":"http:\/\/www.pjh.fr\/wordpress\/?page_id=114","title":{"rendered":"IPSSWM 2009"},"content":{"rendered":"

International Prognostic Staging System for WM <\/sup>(IPSSWM)<\/h1>\n

Morel, P., Duhamel, A., Gobbi, P., Dimopoulos, M. A., Dhodapkar, M. V., McCoy, J., Crowley, J., Ocio, E. M., Garcia-Sanz, R., Treon, S. P., Leblond, V., Kyle, R. A., Barlogie, B. and Merlini, G. (2009), \u00ab\u00a0International prognostic scoring system for Waldenstrom macroglobulinemia\u00a0\u00bb, Blood<\/em>, <\/strong>113, <\/strong>18: 4163-70.<\/strong><\/a><\/p><\/blockquote>\n

5 facteurs de risque<\/strong> (si pr\u00e9sent : 1 point)<\/p>\n\n\n\n\n\n\n\n\n
Facteurs de risque <\/strong><\/td>\nNombre de facteurs
\n<\/strong><\/td>\n		Groupe
\n<\/strong><\/td>\n		Survie \u00e0 5 ans
\n<\/strong><\/td>\n		m\u00e9diane de survie
\n<\/strong><\/td>\n<\/tr>\n
Age\u00a0 > 65 ans<\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
H\u00e9moglobine < ou = 11.5 g\/dL
\n<\/strong><\/td>\n		Age < ou = 65 ans
\net 0-1<\/td>\n		Low\/faible<\/td>\n87%<\/td>\n142.5<\/td>\n<\/tr>\n
Plaquettes < ou = 100 000\/mm3<\/sup>
\n<\/strong><\/td>\n		Age > 65 ans ou 2<\/td>\nInterm\u00e9diaire<\/td>\n68%<\/td>\n98.6<\/td>\n<\/tr>\n
Beta2-microglobuline > 3 mg\/L<\/strong><\/td>\n3 ou +<\/td>\nHigh\/\u00e9lev\u00e9<\/td>\n36%<\/td>\n43.5<\/td>\n<\/tr>\n
Prot\u00e9ine monoclonale s\u00e9rique > 70 g\/L
\n<\/strong><\/td>\n		<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\"\"<\/a><\/p>\n

\"\"<\/a><\/p>\n

Figure 2.<\/strong> ISSWM: staging by age and treatment<\/strong>.
\n(A) Patient age 65 years or less. (B) Patient age more than 65 years.
\n(C) Standard alkylating-based chemotherapy<\/strong>. (D) Purine analog therapy<\/strong>. P<\/em> < .001 for each plot.<\/p>\n

Valable aussi chez les patients ayant re\u00e7u du rituximab…<\/strong><\/p>\n

NB : 96% des patients ont re\u00e7u un traitement de premi\u00e8re ligne avec des agents alkylants ou des analogues nucl\u00e9osidiques. L’IPSSWM a \u00e9t\u00e9 valid\u00e9 sur une seconde s\u00e9rie de patients trait\u00e9s par rituximab <\/strong>seul ou en association avec de la dexamethasone et du cyclophosmadie (RCD).
\nDimopoulos M, Kastritis E, Delimpassi S, et al: The International Prognostic Scoring System for Waldenstrom’s macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica 93:1420-1422, 2008<\/strong><\/em><\/a><\/p><\/blockquote>\n\n

\t
\t\t \t\t\"\"<\/a> \t\t  <\/span> \t\tEnvoyer l'article en PDF<\/span> \t\t  <\/span> \t\t \t\t \t<\/form> <\/div>","protected":false},"excerpt":{"rendered":"

International Prognostic Staging System for WM (IPSSWM) Morel, P., Duhamel, A., Gobbi, P., Dimopoulos, M. A., Dhodapkar, M. V., McCoy, J., Crowley, J., Ocio, E. M., Garcia-Sanz, R., Treon, S. P., Leblond, V., Kyle, R. A., Barlogie, B. and Merlini, G. (2009), \u00ab\u00a0International prognostic scoring system for Waldenstrom macroglobulinemia\u00a0\u00bb, Blood, 113, 18: 4163-70. 5 facteurs […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":24,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","meta":[],"_links":{"self":[{"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=\/wp\/v2\/pages\/114"}],"collection":[{"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=114"}],"version-history":[{"count":2,"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=\/wp\/v2\/pages\/114\/revisions"}],"predecessor-version":[{"id":118,"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=\/wp\/v2\/pages\/114\/revisions\/118"}],"up":[{"embeddable":true,"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=\/wp\/v2\/pages\/24"}],"wp:attachment":[{"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}